Strimvelis

gsk

Pharma

Cost watchdogs back Glaxo's $714K gene therapy

The numbers behind NICE's choice to endorse Strimvelis show just how tough it can be to make money from gene therapy.

Eric Sagonowsky Jan 4, 2018 10:39am

GSK picks up NICE recommendation for Strimvelis

Oct 23, 2017 11:57am

gsk

GSK's talk of selling out points up rare disease challenges

Jul 27, 2017 10:36am

glybera

UniQure gives up on $1M+ gene therapy Glybera

Apr 20, 2017 10:21am